Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

Lung cancer is a highly prevalent disease worldwide in women and men. In 2022, lung cancer stood as the most frequently diagnosed cancer with approximately 2.48 million new cases on a global scale, followed by cancers of the female breast (11.6%), colorectum (9.6%), prostate (7.3%), and stomach (4.9%). Lung cancer is the leading cause of cancer death worldwide according to data provided by the International Agency for Research on Cancer. In 2022 they estimated a 1.8 million deaths across the world. Specifically in Spain, from 1980 to 2022, lung cancer led to 745,182 deaths. Histologically, l

Trial Details

NCT ID
NCT06992609
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Durvalumab
Locations (sample)
  • A Coruña, Spain|43.37135,-8.396
  • Badajoz, Spain|38.87789,-6.97061
  • Barakaldo, Spain|43.29639,-2.98813
  • Barcelona, Spain|41.38879,2.15899
  • Barcelona, Spain|41.38879,2.15899

Key Eligibility Criteria

  • Female or male patients aged ≥18 years at the time of signing the Informed Consent Form (ICF).
  • Written informed consent obtained from the patient/legal representative prior to performing any protocol-related procedures. Additionally, signed a…
  • Patients must have histologically or cytologically documented limited stage SCLC (stage I-III SCLC \[T any, N any, M0\] according to the AJCC Cance…
  • WHO/ECOG PS of 0, 1 or 2 at enrolment, after CRT. A maximum of 20% of patients with ECOG 2 is allowed.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →